Two Sigma Investments, LP Tcr2 Therapeutics Inc. Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.0 - $1.62 $84,677 - $137,176	-84,677 Reduced 70.17%	36,000 $54,000
Q4 2022 Feb 14, 2023	SELL	$0.83 - $1.44 $141,839 - $246,083	-170,891 Reduced 58.61%	120,677 $120,000
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $70,845 - $142,833	-38,089 Reduced 11.55%	291,568 $525,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $865,357 - $1.21 Million	-410,122 Reduced 55.44%	329,657 $956,000
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $59,100 - $115,983	-24,625 Reduced 3.22%	739,779 $2.04 Million

Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $2.03 Million - $3.69 Million	442,545 Added 137.5%	764,404 $3.56 Million
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $535,205 - $1.16 Million	63,413 Added 24.54%	321,859 $2.74 Million
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $654,414 - $985,410	-39,879 Reduced 13.37%	258,446 $4.24 Million
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $3.84 Million - $6.42 Million	188,534 Added 171.72%	298,325 $6.59 Million
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $1.89 Million - $3.25 Million	99,473 Added 964.07%	109,791 $3.4 Million
Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $135,165 - $213,479	10,318 New	10,318 $210,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.